Conference call on Interim Report
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the Interim Report January – September 2016. The presentation will be held in English.
Time: Thursday, October 27, 2016 at 3.00 p.m. CET
Registration can preferably be done in advance under the following link:
or shortly before time of the conference starts on:
Sweden dial in number: +46 (0) 8-506 921 80
International dial in number: +44 (0) 2071 928 000
Conference name: XVIVO Perfusion, conference ID: 94108581
Participants from XVIVO Perfusion:
Magnus Nilsson, CEO
Christoffer Rosenblad, CFO
The press release for XVIVO Perfusion’s Interim Report January – September 2016 will be released before the conference call October 27, 2016.
Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com/corporate/.
October 21, 2016
XVIVO Perfusion AB (publ)
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com